CONSOLIDATED STATEMENTS OF EARNINGS (USD $) In Millions, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Product net sales	$ 5,708.8	$ 5,347.1	$ 4,819.6
Other revenues	97.3	72.0	99.8
Total revenues	5,806.1	5,419.1	4,919.4
Operating costs and expenses:
Cost of sales (excludes amortization of intangible assets)	775.5	748.7	722.0
Selling, general and administrative	2,268.4	2,246.6	2,017.6
Research and development	989.6	902.8	804.6
Amortization of intangible assets	131.3	127.6	138.0
Legal settlement	0	0	609.2
Impairment of intangible assets and related costs	22.3	23.7	369.1
Restructuring charges	5.7	4.6	0.3
Operating income	1,613.3	1,365.1	258.6
Non-operating income (expense):
Interest income	6.7	6.9	7.3
Interest expense	(63.6)	(71.8)	(78.7)
Other, net	(23.1)	(0.5)	(16.4)
Total non-operating income (expense)	(80.0)	(65.4)	(87.8)
Earnings before income taxes	1,533.3	1,299.7	170.8
Provision for income taxes	430.8	361.6	165.9
Net earnings	1,102.5	938.1	4.9
Net earnings attributable to noncontrolling interest	3.7	3.6	4.3
Net earnings attributable to Allergan, Inc.	$ 1,098.8	$ 934.5	$ 0.6
Earnings per share attributable to Allergan, Inc. stockholders:
Basic (in dollars per share)	$ 3.64	$ 3.07	$ 0.00
Diluted (in dollars per share)	$ 3.58	$ 3.01	$ 0.00